New pill for diabetic kidney disease enters human testing

NCT ID NCT06666283

Recruiting now Disease control Sponsor: Alebund Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new oral drug called AP303 in 18 people with diabetic kidney disease. The main goal is to check the drug's safety and how the body processes it over two weeks. Participants will be randomly assigned to receive either AP303 or a placebo, and researchers will monitor side effects and drug levels in the blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AP303
What this could lead to: If successful, this could lead to a new oral treatment option for diabetic kidney disease, potentially helping to slow disease progression.
What could go wrong: This is a very early Phase 1 trial with only 18 participants, so results may not apply to everyone. The main goal is safety, not yet effectiveness, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetic kidney disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETIC KIDNEY DISEASE

Contacts and locations

Locations

Peking University First Hospital
RECRUITING

Beijing, Beijing Municipality, 100009, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.